Education is key, but another critical reason lies in the challenges of reimbursement for NGS in oncology. With more consistent / feasible levels of NGS testing reimbursement for necessary biomarkers, clinical utilization of NGS will absolutely increase and drive more localized testing as hospitals / practice groups gain a better line-of-sight on payback for NGS technology investments. Currently, a majority of US oncologists / hematologists are reliant on outsourced large central labs, who they themselves, are struggling to remain solvent without external investments.
Education is key, but another critical reason lies in the challenges of reimbursement for NGS in oncology. With more consistent / feasible levels of NGS testing reimbursement for necessary biomarkers, clinical utilization of NGS will absolutely increase and drive more localized testing as hospitals / practice groups gain a better line-of-sight on payback for NGS technology investments. Currently, a majority of US oncologists / hematologists are reliant on outsourced large central labs, who they themselves, are struggling to remain solvent without external investments.
Such an excellent point, Brian. Thank you.